Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

245.37 -4.01 (-1.61%)

Streaming Delayed Price Updated: 12:34 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

April 26, 2024

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗

April 17, 2024

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

Via InvestorPlace

Topics ETFs

7 Stable Stocks for 50% Returns by Early 2025 ↗

April 15, 2024

These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries.

Via InvestorPlace

Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

April 05, 2024

INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

April 03, 2024

From Insulet Corporation

Via Business Wire

Analyst Scoreboard: 5 Ratings For Insulet ↗

February 23, 2024

Via Benzinga

Insulet: Q4 Earnings Insights ↗

February 22, 2024

Via Benzinga

Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months ↗

March 31, 2024

Over the past 12 months, 10 Large-Cap stocks have underperformed all others.

Via Talk Markets

5 Stocks To Buy On The Dip To Gain From The Wall Street Rally ↗

March 23, 2024

Wall Street had a dream run in 2023, reversing the nightmare of 2022. The impressive bull run appears set to continue in 2024. Thus, here is a look at some stocks that may be worth buying on the dip...

Via Talk Markets

Insulet Appoints Ana Maria Chadwick as Chief Financial Officer

March 20, 2024

From Insulet Corporation

Via Business Wire

Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 14, 2024

INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating.

Via Chartmill

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

Should you consider NASDAQ:PODD for growth investing? ↗

February 01, 2024

Exploring INSULET CORP (NASDAQ:PODD)'s growth characteristics.

Via Chartmill

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

March 08, 2024

From Insulet Corporation

Via Business Wire

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

March 05, 2024

From Insulet Corporation

Via Business Wire

Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks? ↗

March 04, 2024

A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying.

Via The Motley Fool

Topics Stocks

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗

February 29, 2024

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

Via Benzinga

Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday ↗

February 26, 2024

U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak...

Via Benzinga

Topics Stocks

DexCom: A Winner In Diabetes Management ↗

February 25, 2024

Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820...

Via Talk Markets

Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts ↗

February 23, 2024

After the exuberance seen on Thursday, investors may assess whether it was an irrational one, and futures trading on Friday reflects edginess.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 22, 2024

Via Benzinga

Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)

February 22, 2024

From Insulet Corporation

Via Business Wire

Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum ↗

February 22, 2024

Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings.

Via Benzinga

Topics Economy Stocks

Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference

February 13, 2024

From Insulet Corporation

Via Business Wire

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor

February 07, 2024

From Insulet Corporation

Via Business Wire

5 top healthcare stocks for earnings growth in 2024

January 25, 2024

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

Via MarketBeat

MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs

January 22, 2024

With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs.

Via MarketBeat

Topics Earnings

Insulet Announces Changes to Board of Directors with Retirements and New Appointments

January 18, 2024

From Insulet Corporation

Via Business Wire

Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

January 11, 2024

From Insulet Corporation

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.